De gauche à droite : M. Gilles Rubinstenn, président et fondateur de ReST Therapeutics, Mme Noélie Davezac, vice-présidente Science et Société Université de Toulouse, Jocelyn Méré, délégué régional CNRS Occitanie Ouest.
The creation of the LabCom Trans NMDA (N-methyl-D-aspartate neurotransmitter) joint laboratory between the CNRS, the University of Toulouse and ReST therapeutics was formalised on 6 February at the CBI. This laboratory is a synergy of skills designed to address major public health problems in neurology and neuropsychiatry.
The Centre de recherches sur la cognition animale (CRCA-CBI) is one of three laboratories in Toulouse, along with the Laboratoire d’hétérochimie fondamentale et appliquée (LHFA) and the Institut de pharmacologie et biologie structurale (IPBS), which have joined forces with ReST Therapeutics to form this LabCom.
Using a translational approach extending from the molecule to the brain, it aims to translate fundamental advances in neuroscience into practical, accessible therapeutic solutions for patients suffering from PTSD.
By structuring an integrated pharmacology cluster, the Trans NMDA LabCom will cover the entire process of developing new compounds, from their synthesis to their pharmacological evaluation in vitro and in vivo.
Latest news
